Table 2.
PDX donor clinical and pathologic information
| Total specimens | PDX Formation | No growth | Take Rate | P-value | |
|---|---|---|---|---|---|
| Site | |||||
| Oropharynx | 9 | 8 | 1 | 88.9% | 0.80 |
| Pharynx | 3 | 3 | 0 | 100.0% | |
| Oral cavity | 39 | 32 | 7 | 82.1% | |
| Lymph node | 11 | 8 | 3 | 72.7% | |
| Larynx | 9 | 7 | 2 | 77.8% | |
| AJCC Stage | |||||
| Stage I/II | 11 | 8 | 3 | 72.7% | 0.37 |
| Stage III | 13 | 9 | 4 | 69.2% | |
| Stage IV | 35 | 30 | 5 | 85.7% | |
| Unknown | 12 | 11 | 1 | 91.7% | |
| Age (years) | |||||
| years=<55 | 26 | 23 | 2 | 88.5% | 0.36 |
| 56–60 | 17 | 16 | 1 | 94.1% | |
| 61–67 | 15 | 10 | 5 | 66.7% | |
| >=68 | 13 | 11 | 2 | 84.6% | |
| Gender | |||||
| Male | 58 | 47 | 11 | 81.0% | 1 |
| Female | 13 | 11 | 2 | 84.6% | |
| HPV Status | |||||
| Positive | 5 | 4 | 1 | 80.0% | NA |
| Negative | 66 | 54 | 12 | 81.8% |